Therefore, we can make reasonable conjecture that TDF can lower the risk of HCC by achieving larger reduction of HBsAg, which might be illustrated by higher level of IFN-λ3 in TDF-administrated patients. This evidence concerns the gene IFNL3 and hepatocellular carcinoma.